Cadent Therapeutics Stock

cadenttx.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $67.4MM

Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Cadent Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Cadent Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cadent Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Timothy Piser Ph.D
Chief Scientific Officer
David Anderson Ph.D
Head of Discovery Operations
John McBride
Chief Financial Officer
Robert Volkmann Ph.D
Vice President of Chemistry & Advisor
Michael Curtis Ph.D
President & Chief Executive Officer
Christopher Kenney
Chief Medical Officer

Board Members

Daniel Behr
Mark McDade
Qiming Venture Partners
Richard Horan
Slater Technology Fund
Benjamin Bronstein MD
Clal Biotechnology Industries
Franz Hefti
Cadent Therapeutics
Paul Wotton Ph.D
Timothy Anderson
Cowen Group
David Grayzel MD
Atlas Venture
James Bristol Ph.D
Peter Barrett Ph.D
Atlas Venture
William Koster Ph.D
Clal Biotechnology Industries
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.